Skip to main content
Galvanize Therapeutics, Inc.Form D offering

Galvanize Therapeutics, Inc. filed a Form D with the SEC, reporting $136.2M sold, of a $136.2M offering.

What happened

Galvanize Therapeutics develops pulsed electric field (PEF) energy devices for soft tissue ablation and endoscopic care, including the Aliya and RheOx systems. This Form D reports a cash raise of $136,185,232, which signals substantial capital available to support commercialization and makes the company relevant to vendors serving medtech growth.

Source

Extracted by Autobound

From the Signal API record
Signal
Form D offering

What this signalsNew funding often brings new budget and vendor reviews.

Amount
$136M
Industry group
Biotechnology
Headquarters
Redwood City, CA
Location
REDWOOD CITY, CALIFORNIA
Filed
Nov 18, 2026
Jurisdiction
Delaware

More form D offering signals at other companies

The full record

From the Signal API record

People

  • Doug GodshallExecutive Officer, Director · Named in the filing
  • Seth HarrisonDirector · Named in the filing
  • Antoine PapiernikDirector · Named in the filing
  • Zack ScottDirector · Named in the filing
  • David LewisDirector · Named in the filing
  • Steve AnheierExecutive Officer · Named in the filing
  • Isaac ZachariasDirector · Named in the filing
  • Laura FrancisDirector · Named in the filing

Numbers

Amount (USD)
$136M
Investors
26

Details

CIK
0001659073
Form
D
Entity type
Corporation
Primary topic
Biotech/MedTech Growth
Revenue range
Decline to Disclose
Business state
CA
Accession number
0001659073-26-000004
Resolved entity type
Operating company
Has non accredited investors
No
Filer
Galvanize Therapeutics, Inc.

Topics and mentions

Topics

  • Biotechnology
  • Medical Devices
  • Commercialization
  • Clinical Evidence
  • Growth Capital

Exemptions

  • 06b

Securities

  • Equity

Extraction

Confidence
High
Relevance
80%
Detected
Nov 18, 2026
signal_type
sec-form-d-funding
signal_subtype
newFilingCompany

Use this data

Get every form D offering signal for Galvanize Therapeutics, Inc. and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Galvanize Therapeutics, Inc. this week?”

  2. Send it to your own tools

    The Signal API returns form D offering signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-form-d-funding record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/fd-0001659073-26-000004 returns this record as JSON. POST /v1/companies/enrich returns every signal for galvanizetx.com.

{
  "signal_id": "fd-0001659073-26-000004",
  "signal_type": "sec-form-d-funding",
  "signal_subtype": "newFilingCompany",
  "detected_at": "2026-11-18T00:00:00+00:00",
  "company": {
    "name": "Galvanize Therapeutics, Inc.",
    "domain": "galvanizetx.com"
  },
  "data": {
    "cik": "0001659073",
    "phone": "650-268-4252",
    "detail": "The filing suggests a growth-stage biotechnology company moving from clinical adoption into broader commercial execution, with spend likely flowing toward product development, regulatory work, clinical evidence, manufacturing, and market expansion. Vendors should pay attention to opportunities around device manufacturing, quality systems, clinical operations, hospital sales enablement, and go-to-market infrastructure as the company scales deployment across providers.",
    "topics": [
      "Biotechnology",
      "Medical Devices",
      "Commercialization",
      "Clinical Evidence",
      "Growth Capital"
    ],
    "summary": "Galvanize Therapeutics develops pulsed electric field (PEF) energy devices for soft tissue ablation and endoscopic care, including the Aliya and RheOx systems. This Form D reports a cash raise of $136,185,232, which signals substantial capital available to support commercialization and makes the company relevant to vendors serving medtech growth.",
    "website": "https://galvanizetx.com",
    "location": "REDWOOD CITY, CALIFORNIA",
    "file_date": "2026-11-18",
    "form_type": "D",
    "relevance": 0.8,
    "confidence": "high",
    "exemptions": [
      "06b"
    ],
    "filing_url": "https://www.sec.gov/Archives/edgar/data/1659073/000165907326000004/",
    "source_url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001659073&type=D&dateb=&owner=include&count=40",
    "entity_name": "Galvanize Therapeutics, Inc.",
    "entity_type": "Corporation",
    "jurisdiction": "DELAWARE",
    "primary_topic": "Biotech/MedTech Growth",
    "revenue_range": "Decline to Disclose",
    "business_state": "CA",
    "industry_group": "Biotechnology",
    "related_persons": [
      {
        "name": "Doug Godshall",
        "roles": [
          "Executive Officer",
          "Director"
        ]
      },
      {
        "name": "Seth Harrison",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Antoine Papiernik",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Zack Scott",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "David Lewis",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Steve Anheier",
        "roles": [
          "Executive Officer"
        ]
      },
      {
        "name": "Isaac Zacharias",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Laura Francis",
        "roles": [
          "Director"
        ]
      }
    ],
    "total_investors": 26,
    "accession_number": "0001659073-26-000004",
    "securities_types": [
      "Equity"
    ],
    "business_location": "Redwood City, CA",
    "total_amount_sold": 136185232,
    "resolved_entity_name": "Galvanize Therapeutics, Inc.",
    "resolved_entity_type": "operating_company",
    "total_offering_amount": 136185232,
    "company_domain_confidence": 10,
    "has_non_accredited_investors": false
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.